GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EyeGene Inc (XKRX:185490) » Definitions » Institutional Ownership

EyeGene (XKRX:185490) Institutional Ownership : 0.14% (As of May. 19, 2024)


View and export this data going back to 2015. Start your Free Trial

What is EyeGene Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, EyeGene's institutional ownership is 0.14%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, EyeGene's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, EyeGene's Float Percentage Of Total Shares Outstanding is 0.00%.


EyeGene Institutional Ownership Historical Data

The historical data trend for EyeGene's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EyeGene Institutional Ownership Chart

EyeGene Historical Data

The historical data trend for EyeGene can be seen below:

2023-05-31 2023-06-30 2023-07-31 2023-08-31 2023-09-30 2023-10-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30
Institutional Ownership 0.13 0.12 0.10 0.07 0.05 0.01 0.14 0.14 0.14 0.14

EyeGene Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


EyeGene (XKRX:185490) Business Description

Traded in Other Exchanges
N/A
Address
Gangseo-gu, Seoul 401, B-dong 910 Gayang-dong, Seoul, KOR, 07528
EyeGene Inc is a South Korea based bio-venture company. It researches and develops biopharmaceuticals. Its products include EG-Mirotin, EG-HPV, EGVac systems. It provides drugs for the treatment of age-related degenerative diseases. Its products target diabetic retinopathy.

EyeGene (XKRX:185490) Headlines

No Headlines